
ImmuPharma appoints Kymos as bioanalytical partner for diabetes drug Kapiglucagon development
ImmuPharma has appointed Kymos Group as the bioanalytical partner for its diabetes drug candidate Kapiglucagon, completing its outsourced development team. Kymos will develop and validate methods to measure the drug in biological samples and analyze ...

